BB Biotech (BION) AI Stock Analysis

• Market Cap: CHF2.58B
• Dividend Yield: 3.95%
• Average Volume (3M): 98.23K
• Price to Earnings (P/E): 15.6
• Beta (1Y): 0.93
• Revenue Growth: 83.74%
• EPS Growth: 31.82%
• Country: CH
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 55,400,000
• 10 Day Avg. Volume: 119,513
• 30 Day Avg. Volume: 98,228
• PEG Ratio: -0.19
• Price to Book (P/B): 0.85
• Price to Sales (P/S): 17.44
• P/FCF Ratio: 6.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: CHF54.00 ▲(9.42% Upside)

The score is driven primarily by improved 2024 financial performance (profitability, cash flow, and low leverage) but tempered by pronounced historical volatility. Technicals add support via an uptrend and positive MACD, while valuation is reasonable with a ~3.95% dividend yield.

Positive Factors

Sector-focused investment vehicle

A dedicated biotech investment vehicle concentrates domain expertise and research resources on one sector, enabling informed stock selection and thematic exposure. Over months this focused approach supports the potential for outperformance through active allocation to innovation and catalyst-driven winners.

Rebound in 2024 profitability and cash flow

Sustained positive net income and stronger operating cash flow in 2024 indicate improved portfolio realization and cash generation capacity. Over the medium term this enhances financial flexibility, reduces forced asset sales, and supports reinvestment or distributions without increasing leverage materially.

Strengthened operating and free cash flow

Recovering and meaningful free cash flow creates a durable buffer for an investment vehicle: it funds dividends, covers operating costs, and provides dry powder for opportunistic purchases. Over several quarters, stronger cash flow reduces liquidity risk during biotech market drawdowns.

Negative Factors

High historical volatility of results

Marked multi-year volatility shows portfolio valuations and operating metrics swing widely with biotech cycles. This structural volatility complicates forecasting, may force realizations at unfavorable times, and weakens predictability of NAV and income across 2–6 months.

Unpredictable revenue and earnings profile

Large revenue and earnings swings reflect dependence on timing of portfolio events and valuation shifts. Over the medium term this undermines reliable earnings streams and makes distribution planning and long-term performance assessment dependent on episodic realizations rather than steady operational income.

Performance tied to biotech market and concentration

As an actively managed, concentrated biotech portfolio, long-term returns hinge on market cycles and stock-picking skill. This structural dependence increases idiosyncratic and sector cyclicality risk, limiting diversification benefits and making performance sensitive to manager decisions and biotech sentiment over months.

BB Biotech Business Overview & Revenue Model

Company Description

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.

How the Company Makes Money

BB Biotech makes money through its investment activities in the biotechnology sector. The company generates revenue primarily from the appreciation of its investments in biotechnology companies. This includes capital gains realized from selling shares of companies within its portfolio at a profit. BB Biotech also earns income from dividends distributed by the companies in which it holds equity. The company's success is closely tied to the performance of its portfolio companies, which can be influenced by factors such as successful clinical trial results, regulatory approvals, and market demand for new therapies. Additionally, BB Biotech may engage in strategic partnerships or collaborations to enhance its investment opportunities and returns.

BB Biotech Financial Statement Overview

Summary

2024 shows a clear rebound with positive net income, improved cash generation, and a conservatively positioned balance sheet with modest leverage. However, results across 2021–2024 have been highly volatile (including sharp revenue swings and prior losses/negative operating cash flow), reducing confidence in the durability of the recovery.

Income Statement

Profitability in 2024 rebounded sharply with strong margins and positive net income, following large losses in 2021–2023. However, revenue has been highly volatile (including a steep decline in 2024 versus 2023 and negative revenue in 2021), which makes the earnings profile less predictable and lowers confidence in the durability of the turnaround.

Balance Sheet

The balance sheet looks conservatively positioned: debt levels are modest relative to equity, and leverage improved materially in 2024 versus 2021–2023. That said, returns on equity have been inconsistent—negative in 2021–2023 before turning slightly positive in 2024—highlighting sensitivity to portfolio/valuation swings and less stable value creation through the cycle.

Cash Flow

Cash generation strengthened in 2023–2024 with solid positive operating cash flow and meaningful free-cash-flow growth in 2024. The main weakness is volatility: operating cash flow was negative in 2021–2022, indicating that cash generation can swing materially year-to-year, even if recent results are much improved.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-176.15M	111.63M	35.00K	4.00K	-396.22M	699.23M
Gross Profit	-176.15M	111.63M	35.00K	4.00K	-396.22M	699.23M
EBITDA	0.00	80.24M	-201.26M	-357.29M	-402.79M	691.25M
Net Income	-438.69M	75.90M	-206.61M	-357.81M	-404.81M	691.17M
Balance Sheet
Total Assets	1.84B	2.41B	2.64B	3.05B	3.64B	3.96B
Cash, Cash Equivalents and Short-Term Investments	2.16M	2.41B	2.64B	3.05B	3.64B	3.96B
Total Debt	0.00	117.50M	304.90M	363.00M	355.00M	63.00M
Total Liabilities	2.43M	121.11M	313.94M	367.25M	355.00M	63.00M
Stockholders Equity	1.84B	2.29B	2.32B	2.69B	3.28B	3.89B
Cash Flow
Free Cash Flow	435.73M	304.56M	218.28M	-357.81M	-94.79M	262.45M
Operating Cash Flow	435.73M	304.56M	218.28M	-357.81M	-94.79M	262.45M
Investing Cash Flow	0.00	0.00	0.00	588.94M	0.00	0.00
Financing Cash Flow	-427.20M	-305.20M	-220.21M	-233.27M	91.77M	-284.48M

BB Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 49.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BION, the sentiment is Positive. The current price of 49.35 is above the 20-day moving average (MA) of 47.65, above the 50-day MA of 45.93, and above the 200-day MA of 36.43, indicating a neutral trend. The MACD of 0.39 indicates Positive momentum. The RSI at 51.75 is Neutral, neither overbought nor oversold. The STOCH value of 22.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BION.

BB Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSLN	73 Outperform	CHF667.52M	9.45	―	―	58.51%	―
BION	68 Neutral	CHF2.58B	15.62	-20.74%	3.95%	83.74%	31.82%
NWRN	67 Neutral	CHF400.29M	16.82	―	―	744.64%	―
KURN	61 Neutral	CHF1.01B	-162.84	-7.82%	―	104.01%	33.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MOLN	48 Neutral	CHF143.33M	-2.11	-49.86%	―	-100.00%	14.45%
IDIA	46 Neutral	CHF903.87M	-5.41	―	―	229.23%	63.47%

BB Biotech Corporate Events

BB Biotech Forecasts Surge in 2025 Profit to CHF 578 Million

BB Biotech AG expects to report an unaudited profit of around CHF 578 million for the 2025 financial year, a sharp increase from CHF 76 million a year earlier, reflecting strong share price performance among the biotech companies in its portfolio. The company plans to publish detailed portfolio information and its full annual report on 20 February 2026, with the robust result underlining its positioning as a major specialist investor in the biotech sector and signaling significant value creation for shareholders over the past year.

The most recent analyst rating on (CH:BION) stock is a Buy with a CHF56.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.

BB Biotech posts strong 2025 rebound and lifts dividend after biotech outperformance

BB Biotech AG reported a sharp turnaround in 2025 with a preliminary net profit of CHF 578 million versus CHF 76 million a year earlier, driven by a strong share price total return of up to 53.7% in USD terms and net asset value gains that outpaced the Nasdaq Biotechnology Index for both the full year and the fourth quarter. The company’s share discount to NAV narrowed to 10.8% at year-end amid improving investor sentiment, and the board will ask shareholders to approve a higher ordinary dividend of CHF 2.25 per share for 2026, implying a 5% yield and underscoring its intention to balance robust shareholder payouts with continued reinvestment in long-term biotech growth opportunities.

The most recent analyst rating on (CH:BION) stock is a Buy with a CHF56.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.